Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Zhanhong Wu, Nai‐Kong V. Cheung
Pharmacology & Therapeutics (2017) Vol. 182, pp. 161-175
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries, et al.
Pharmacology & Therapeutics (2019) Vol. 201, pp. 103-119
Open Access | Times Cited: 243
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Adam Bates, Christopher Power
Antibodies (2019) Vol. 8, Iss. 2, pp. 28-28
Open Access | Times Cited: 173
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Jim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 287-287
Open Access | Times Cited: 105
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 35
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A Park, Nai‐Kong V. Cheung
Journal of Clinical Oncology (2020) Vol. 38, Iss. 16, pp. 1836-1848
Open Access | Times Cited: 106
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bushra Husain, Diego Ellerman
BioDrugs (2018) Vol. 32, Iss. 5, pp. 441-464
Open Access | Times Cited: 96
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 90
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein, Duy Pham, Ute Schellenberger, et al.
mAbs (2019) Vol. 11, Iss. 4, pp. 639-652
Open Access | Times Cited: 84
Recent advances and challenges of bispecific antibodies in solid tumors
Yuze Wu, Ming Yi, Shuangli Zhu, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 65
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka, Wolfgang Schaefer, Christian Klein
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 59
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance
Joanna Pastwińska, Kaja Karaś, Iwona Karwaciak, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 4, pp. 188754-188754
Open Access | Times Cited: 42
Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer
Jian Chen, Tianchuan Zhu, Guanmin Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 40
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Yeji Hong, Su-Min Nam, Aree Moon
Archives of Pharmacal Research (2023) Vol. 46, Iss. 3, pp. 131-148
Closed Access | Times Cited: 39
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours
Kate L. Lowe, David K. Cole, Rupert Kenefeck, et al.
Cancer Treatment Reviews (2019) Vol. 77, pp. 35-43
Open Access | Times Cited: 73
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
Brian H. Santich, Jeong A Park, Hoa Tran, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 534
Open Access | Times Cited: 68
Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Omid Vafa, Nathan D. Trinklein
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 68
Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies
Dana L. Casey, Nai‐Kong V. Cheung
Cancer Immunology Research (2020) Vol. 8, Iss. 2, pp. 161-166
Open Access | Times Cited: 67
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy
Tara Arvedson, Julie M. Bailis, Carolyn D. Britten, et al.
Annual Review of Cancer Biology (2021) Vol. 6, Iss. 1, pp. 17-34
Open Access | Times Cited: 51
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn Clarke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002488-e002488
Open Access | Times Cited: 41
A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
Leila M. Boustany, Sherry L. LaPorte, Laurie Wong, et al.
Cancer Research (2022) Vol. 82, Iss. 22, pp. 4288-4298
Open Access | Times Cited: 31
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Xiaojing Qin, Wenjing Ning, Han Liu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2361-2377
Open Access | Times Cited: 7
Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 41
Open Access | Times Cited: 6
Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency
Linlin Wang, Sayed Shahabuddin Hoseini, Hong Xu, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 12, pp. 2013-2024
Open Access | Times Cited: 46
B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
H. N. Abramson
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5192-5192
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top